These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran. de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921 [TBL] [Abstract][Full Text] [Related]
6. Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved Li J; Liu J; Zhang X; Clausen V; Tran C; Arciprete M; Wang Q; Rocca C; Guan LH; Zhang G; Najarian D; Xu Y; Smith P; Wu JT; Chong S Drug Metab Dispos; 2021 Jul; 49(7):572-580. PubMed ID: 33941543 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E; Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041 [TBL] [Abstract][Full Text] [Related]
8. Givosiran: First Approval. Scott LJ Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693 [TBL] [Abstract][Full Text] [Related]
9. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. Sardh E; Harper P J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977 [TBL] [Abstract][Full Text] [Related]
10. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver. Vassiliou D; Sardh E; Harper P; Simon AR; Clausen VA; Najafian N; Robbie GJ; Agarwal S Clin Pharmacol Ther; 2021 Nov; 110(5):1250-1260. PubMed ID: 34510420 [TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Sardh E; Rejkjaer L; Andersson DE; Harper P Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984 [TBL] [Abstract][Full Text] [Related]
12. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Wang B; Bonkovsky HL; Lim JK; Balwani M Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627 [TBL] [Abstract][Full Text] [Related]
13. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report. Mazzoli M; Ricci A; Vaudano AE; Marcacci M; Marchini S; Bergonzini P; Di Pierro E; Pischik E; Iughetti L; Pietrangelo A; Meletti S; Ventura P Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3268-3274. PubMed ID: 38708485 [TBL] [Abstract][Full Text] [Related]